Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT01088386
Enrolling by invitation Observational

Zyprexa® Relprevv™ Patient Care Program

NCT01088386 · tracked via the Priya Life Science USA tracker
Sponsor
Eli Lilly and Company
Phase
Observational
Started
2010-03-03
Last updated
2026-01-28

Condition(s) studied

Schizophrenia

Study summary

The goal of the Zyprexa Relprevv Patient Care Program is to mitigate the risk of negative outcomes associated with Zyprexa Relprevv post-injection delirium/sedation syndrome (PDSS).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Any patients receiving Zyprexa Relprevv enrolled in Zyprexa Relprevv Patient Care Program Exclusion Criteria: * Any patient not receiving Zyprexa Relprevv

Primary outcome measure(s)

  • Incidence per injection and per patient of post-injection delirium/sedation syndrome (PDSS) events — Baseline to end of study

Trial sites (1)

FacilityCityRegionStatus
United BioSource Corporation Blue Bell Pennsylvania

More Eli Lilly and Company trials in the USA

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms Active, not recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 Active, not recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia Recruiting

Other trials for the same condition

Study of SPG302 in Adults With Schizophrenia Active, not recruiting
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Enrolling by invitation
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01088386 on ClinicalTrials.gov ↗ ← All trials in the USA